Citius Pharmaceuticals, Inc.
Datakwaliteit: 83%
CTXR
Nasdaq
Manufacturing
Chemicals
€ 0,84
▲
€ 0,01
(1,49%)
Marktkapitalisatie: 18,85 M
Prijs
€ 0,84
Marktkapitalisatie
18,85 M
Dagbereik
€ 0,80 — € 0,87
52-Weeksbereik
€ 0,63 — € 2,48
Volume
232.499
Openen € 0,82
50D / 200D Gem.
€ 0,79
6,43% above
50D / 200D Gem.
€ 1,16
27,08% below
Quick Summary
Belangrijkste Punten
Negative free cash flow of -34,84 M
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-53,58%
Onder sectorgemiddelde (-53,47%)
ROIC-33,29%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio0,99
Interest Coverage-182,70
Waardering
PE (TTM)
-0,49
Boven sectorgemiddelde (-1,47)
P/B Ratio0,24
EV/EBITDAN/A
Dividend YieldN/A
Koershistorie
Financiële Trends
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)
Sectorvergelijking
vs Manufacturing sector mediaan (1364 peers)| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,5 | -1,5 |
| P/B | 0,2 | 1,6 |
| ROE % | -53,6 | -53,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,8 |
| D/E | — | 0,3 |
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -38,85 M |
| ROE | -53,58% | ROA | -28,99% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -34,84 M |
| ROIC | -33,29% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 0,99 |
| Interest Coverage | -182,70 | Asset Turnover | N/A |
| Working Capital | -261.987 | Tangible Book Value | 70,61 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -0,49 | Forward P/E | N/A |
| P/B Ratio | 0,24 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -184,83% | ||
| Market Cap | 18,85 M | Enterprise Value | 11,13 M |
| Per Share | |||
| EPS (Diluted TTM) | -2,46 | Revenue / Share | N/A |
| FCF / Share | -1,56 | OCF / Share | -1,56 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 89,66% |
| SBC-Adj. FCF | -47,06 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -39,74 M | -39,43 M | -32,54 M | -33,64 M | -23,05 M |
| EPS (Diluted) | -3,38 | -5,97 | — | -0,23 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -38,53 M | -42,00 M | -36,73 M | -33,32 M | -23,53 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 9,16 M | 11,91 M | 14,82 M | 17,66 M | 12,24 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 49.750,0 | — | — | 10.839,0 | 10.839,0 |
| Income Tax | 1,06 M | 576.000,0 | 576.000,0 | 576.000,0 | 1.233,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 130,94 M | 116,65 M | 103,61 M | 114,00 M | 142,43 M |
| Total Liabilities | 53,41 M | 42,55 M | 12,18 M | 10,57 M | 9,65 M |
| Shareholders' Equity | 67,55 M | 70,08 M | 90,83 M | 102,83 M | 132,18 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 4,25 M | 3,25 M | 26,48 M | 41,71 M | 70,07 M |
| Current Assets | 27,93 M | 14,22 M | 34,37 M | 44,56 M | 72,81 M |
| Current Liabilities | 44,91 M | 35,81 M | 5,78 M | 4,53 M | 3,98 M |
{"event":"ticker_viewed","properties":{"ticker":"CTXR","listing_kind":"stock","pathname":"/stocks/ctxr","exchange":"Nasdaq","country":"US"}}